The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer

PD-L1 expression is the routine clinical biomarker for the selection of patients to receive immunotherapy in non-small cell lung cancer (NSCLC). However, the application and best timing of immunotherapy in the resectable setting is still under investigation. We aimed to study the effect of chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Zens, Philipp, Bello, Corina, Scherz, Amina, von Gunten, Michael, Ochsenbein, Adrian, Schmid, Ralph A., Berezowska, Sabina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708547/
https://www.ncbi.nlm.nih.gov/pubmed/35915139
http://dx.doi.org/10.1038/s41379-022-01139-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708547/
https://www.ncbi.nlm.nih.gov/pubmed/35915139
http://dx.doi.org/10.1038/s41379-022-01139-y

Ejemplares similares